Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance

27 Nov 2017

Abstract excerpt

Abstract Antimitotics that target tubulin are among the most useful chemotherapeutic drugs, but their clinical activity is often limited by the development of multidrug resistance. We recently discovered the novel small-molecule DJ101 as a potent and metabolically stable tubulin inhibitor that can circumvent the drug efflux pumps responsible for multidrug resistance of existing tubulin inhibitors. In this study,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Cancer therapeutics and mechanisms
Share to Synthesis and biological activity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29180476
DOI: 10.1158/0008-5472.can-17-0577

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane ResistancePMID 29180476Read ↗

Biological activity of a stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor, 60c, in metastatic, triple-negative breast cancerSemantic proximity Read ↗

PM534, an Optimized Target-Protein Interaction Strategy through the Colchicine Site of TubulinSemantic proximity Read ↗

A review of research progress of antitumor drugs based on tubulin targetsSemantic proximity Read ↗

Design and Biological Evaluation of Novel Tubulin Inhibitors as Antimitotic Agents Using a Pharmacophore Binding Model with TubulinSemantic proximity Read ↗

Azaindole derivatives are inhibitors of microtubule dynamics, with anti‐cancer and anti‐angiogenic activitiesSemantic proximity Read ↗

Class III β-tubulin expression and in vitro resistance to microtubule targeting agentsSemantic proximity Read ↗

Recent advances in research of colchicine binding site inhibitors and their interaction modes with tubulin.Semantic proximity Read ↗

The colchicine derivative CT20126 shows a novel microtubule-modulating activity with apoptosisSemantic proximity Read ↗

Mutations in alpha- and beta-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine.Semantic proximity Read ↗

Tubulin-Targeted Agents Including Docetaxel and CabazitaxelSemantic proximity Read ↗

Structure-Based Pharmacophore Design and Virtual Screening for Novel Tubulin Inhibitors with Potential Anticancer ActivitySemantic proximity Read ↗

Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical TrialsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.